BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Can-Fite BioPharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Can-Fite BioPharma's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07410455-1801@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Piclidenoson: Phase 2 readout est. (NCT07410455)
DESCRIPTION:Piclidenoson\, phase 2.\nStudy: An Open-label\, Phase 2 Pilot S
 tudy on the Efficacy and Safety of Piclidenoson in Patients With Lowe Synd
 rome\nEstimated primary completion: 31 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/piclidenoson#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07410455
URL:https://assetmemo.bio/drug/piclidenoson#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643260-1801@assetmemo.bio
DTSTAMP:20261121T011042Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Piclidenoson: Phase 3 readout est. (NCT06643260)
DESCRIPTION:Piclidenoson\, phase 3\, Psoriasis.\nStudy: A Phase 3 Study in 
 Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and 
 Efficacy\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/piclidenoson#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06643260
URL:https://assetmemo.bio/drug/piclidenoson#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
